Efficacy and safety of intermittent oral 1α(OH)-vitamin D2 in suppressing 2° hyperparathyroidism in hemodialysis patients

Dialysis and Transplantation

Volumn 26, Issue 9, 1997, Pages 583-595+630

  Frazao, Joao M ^a,b   Levine, Barton S ^a,b   Tan Jr , Alexander U ^a,b   Mazess, Richard B ^c   Kyllo, Darlene M ^c   Knutson, Joyce C ^c   Bishop, Charles W ^c   Coburn, Jack W ^a,b  

^a VETERANS AFFAIRS MEDICAL CENTER   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c Bone Care International   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 0000850317     PISSN: 00902934     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (31)

1. Jara A, Bover J, Felsenfeld AJ, Nemeh M, Levine BS. Divalent Ion Metabolism. In: Current Nephrology, Gonick HC (ed.), St. Louis: Mosby-Year Book, Inc., 1995, p. 133.
2. Silver J, Russell J, Sherwood LM. Regulation by vitamin D metabolites of messenger ribonucieic acid for preproparathyroid hormone in isolated bovine parathyroid cells. Proc Nat Acad Sci (USA) 1985, 82:4270-4273.
3. 2D of transcription of the parathyroid hormone gene. Endocrinology 1986; 119:2864-2866.
4. Brown AJ, Ritter CR, Finch JL, Morrissey J, Martin KJ, Murayama E, Nishii Y, Slatopolsky E. The noncalcemic analogue of vitamin D, 22-oxacalcitriol, suppresses parathyroid hormone synthesis and secretion. J Clin Invest 1989; 84:728-732.
5. 2, Suppresses Parathyroid Hormone Secretion in Uremic Rats in the Absence of Hypercalcemia. Am J Kidney Dis 1995, 26 (5):852-860.
6. Kobayashi Y, Taguchi T, Mitsuhashi, et al. Studies on organic fluorine compounds. Studies on steriods Synthesis of 1α, 25-dihydroxy-26, 26, 26, 27, 27, 27-hexafluorovitamin D. Chem Pharm Bull 1982, 30.4297-4303.
7. 2 in hemodialysis patients with moderate to severe secondary hyperparathyroidism Kidney Int 1997; 51:317-323
8. Sherrard DJ, Hercz G, Pei Y, Maloney NA, Greenwood C, Manuel A, Saiphoo C, Fenton SS, Segre GV The spectrum of bone disease in end-stage renal failure: An evolving disorder Kidney Int 1993; 43.436-442.
9. Solal MC, Sebert JL, Boudailliez B, Annick M, Moriniere P, Gueris J, Bouillon R, Fournier A. Comparison of intact, midregion, and carboxy terminal assays of parathyroid hormone for the diagnosis of bone disease in hemodialyzed patients J Clin Endocrinol Metab 1991; 73:516-524.
10. Quarles LD, Lobamugh B, Murphy G. Intact parathyroid hormone overestimates the presence and severity of parathyroid-mediated osseous abnormalities in uremia. J Clin Endocrinol Metab 1992; 75.145-150.
11. Segre GV, Sherrard DJ, Carlton EI. Use of the PTH (IRMA) Assay in Patients with Impaired Renal Function and Renal Osteodystrophy San Juan Capistrano: Nichols Institute, 1990, p. 1.
12. Slatopolsky E, Weerts C, Thielan J, Horst RL, Harter H, Martin KJ. Marked suppression of secondary hyperparathyroidism by intravenous administration of 1,25-dihydroxycholecalciferol in uremic patients. J Clin Invest 1984; 74:2136-2143.
13. Fischer ER, Harris DCH. Comparison of intermittent oral and intravenous calcitriol in hemodialysis patients with secondary hyperparathyroidism Clin Nephrol 1993; 40.216-220.
14. Levine BS, Song MM. Pharmacokinetics and efficacy of pulse oral versus intravenous calcitriol in hemodialysis patients. J Am Soc Nephrol 1996; 7:488-496.
15. Quarles LD, Yohay DA, Carroll BA, Spritzer CE, Minda SA, Baratholomay D, Lobamugh BA Prospective trial of pulse oral versus intravenous calcitriol treatment of hyperparathyroidism in ESRD. Kidney Int 1994; 45:1710-1721
16. Sjöden G, Lindgren JU, Deluca HF Antirachitic activity of 1α-hydroxyergocalciferol and 1α-hydroxycholecalciferol in rats. J Nutr 1984, 114:2043-2046.
17. 2 in the rat. Proc Soc Exp Biol Med 1985, 178 432-436.
18. Sato F, Ouchi Y, Okamoto Y, Kaneki M, Nakamura T, Ikekawa N, Orimo H. Effects of vitamin D. analogs on calcium metabolism in vitamin D-deficient rats and in MC3T3 osteoblastic cells. Res Exp Med 1991. 191:235-242.
19. 2 on calcium homeosiasis in postmenopausal osteopenic women. J Bone Miner Res 1994, 9:607-614.
20. Herrmann P, Ritz E, Schmidt-Gayk H, Schäfer I, Geyer J, Nonnast-Daniel B, Koch K-M, Weber U, Hörl W, Haas-Wörle A, Kühn K, Bierther B, Schneider P. Comparison of intermittent and continuous oral administration of calcitriol in dialysis patients: A randomized prospective trial. Nephron 1994, 67:48-53.
21. Cannella G, Bonucci E, Rolla D, Ballanti P, Moriero E, De Grandi R, Amugeri C, Claudiani F, Di Maio G. Evidence of healing of secondary hyperparathyroidism in chronically hemodialyzed uremic patients treated with long-term intravenous calcitriol. Kidney Int 1994; 46:1124-1132.
22. Rodriguez M, Felsenfeld AJ, Williams C, Pederson JA, Llach F. The effect of long-term calcitriol administration on parathyroid function in hemodialysis patients. J Am Soc Nephrol 1991; 2.1014-1020.
23. Sprague SM, Moe SM. Safety and efficacy of long-term treatment of secondary hyperparathyroidism by low-dose intravenous calcitriol. Am J Kidney Dis 1992; 19:532-539.
24. Gallieni M, Brancaccio D, Padovese P, Rolla D, Bedani P, Colantonio G, Bronzieri C, Bagni B, Tarolo G, (Italian Group for the Study of Intravenous Calcitriol). Low-dose intravenous calcitriol treatment of secondary hyperparathyroidism in hemodialysis patients. Kidney Int 1992; 42.1191-1198.
25. Gonella M, Calabrese G, Aleo AG, Vagelli G, Deambrogio P. Calcitriol pulse therapy for severe hyperparathyroidism or calcium salts as phosphate binders in renal dialysis patients. Nephron 1995; 71.350-353,
26. Malberti F, Surian M, Cosci P. Effect of chronic intravenous calcitriol on parathyroid function and set point of calcium in dialysis patients with refractory secondary hyperparathyroidism. Nephrol Dial Transplant 1992; 7:822-828.
27. Dressler R, Laut J, Lynn RJ, Ginsberg N. Long-term high-dose intravenous calcitnol therapy in end-stage renal disease patients with severe secondary hyperparathyroidism. Clin Nephrol 1995; 43(5).324-331.
28. Llach F, Hervas J, Cerezo S. The Importance of Dosing Intravenous Calcitriol in Dialysis Patients with Severe Hyperparathyroidism. Am J Kidney Dis 1995; 26 (5):845-851
29. 3 on secondary hyperparathyroidism in chronic uremic patients on maintenance hemodialysis Nephron 1989; 53:194-200.
30. Ljunghall S, Althoff P, Fellström B, Marjanovic B, Nisell J, Weiss L, Wide L. Effects on serum parathyroid hormone of intravenous treatment with alphacalcidol in patients on chronic hemodialysis. Nephron 1990; 55:380-385.
31. 3 and low dialysate calcium. Kidney Int 1993; 43(Suppl 41):S121-S124.